Skip to main content

Advertisement

SpringerLink
Log in

Successful treatment of AIDS-associated, primary CNS lymphoma with rituximab- and methotrexate-based chemotherapy and autologous stem cell transplantation

  • Case Report
  • Published:
Infection Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Hoffmann C, Tabrizian S, Wolf E, Eggers C, Stoehr A, Plettenberg A, Buhk T, Stellbrink HJ, Horst HA, Jäger H, Rosenkranz T. Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery. AIDS. 2001;15:2119–27.

    Article  PubMed  CAS  Google Scholar 

  2. Wolf T, Brodt HR, Fichtlscherer S, Mantzsch K, Hoelzer D, Helm EB, Mitrou PS, Chow KU. Changing incidence and prognostic factors of survival in AIDS-related non-Hodgkin’s lymphoma in the era of highly active antiretroviral therapy (HAART). Leuk Lymphoma. 2005;46:207–15.

    Article  PubMed  Google Scholar 

  3. Illerhaus G, Marks R, Ihorst G, Guttenberger R, Ostertag C, Derigs G, Frickhofen N, Feuerhake F, Volk B, Finke J. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol. 2006;24:3865–70.

    Article  PubMed  CAS  Google Scholar 

  4. Illerhaus G, Müller F, Feuerhake F, Schäfer AO, Ostertag C, Finke J. High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica. 2008;93:147–8.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

There was no financial or material support provided for this work. TW had board memberships, received consultancy fees, payment for lectures and travel grants from Abbvie, BMS, Gilead, MSD, Oxford Immunotec and ViiV. HRB had board memberships, received consultancy fees, payment for lectures and travel grants from Gilead, Janssen, MSD, Pfizer and ViiV. CS received consultancy fees from Abbvie, BMS, Boehringer, Gilead, Janssen, MSD, ViiV. JA, GK and CB have no disclosures.

Author information

Authors and Affiliations

  1. Department of Medicine II—Infectious Diseases, HIV Center, Hospital of the J. W. Goethe University, Theodor Stern Kai 7, 60596, Frankfurt, Germany

    T. Wolf, C. Stephan, G. Kann & H.-R. Brodt

  2. Department of Medicine II—Hematology/Oncology, Hospital of the J. W. Goethe University, Frankfurt, Germany

    T. Kiderlen, J. Atta & C. Brandts

Authors
  1. T. Wolf
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Kiderlen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Atta
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Stephan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G. Kann
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H.-R. Brodt
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C. Brandts
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. Wolf.

Additional information

This case was presented at the 14th EACS Conference, October 16–19th, 2013, Brussels, Belgium.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wolf, T., Kiderlen, T., Atta, J. et al. Successful treatment of AIDS-associated, primary CNS lymphoma with rituximab- and methotrexate-based chemotherapy and autologous stem cell transplantation. Infection 42, 445–447 (2014). https://doi.org/10.1007/s15010-013-0579-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15010-013-0579-8

Keywords

Search

Navigation